Detection of Retroviruses and HIV-1 Groups -M and -O Discrimination within Clinical Serum Samples


CDC researchers have developed methods for detecting retroviruses within a patient blood sample and discriminating HIV-1 samples within serum specimens. HIV-1 can be genetically classified into two major groups, group M (major) and Group O (outlier) with group O comprising all divergent viruses that do not cluster with group M. The identification of group O infections raised public health concerns about the safety of the blood supply because HIV-1 screening by group M-based serologic tests does not consistently detect group O infection.

The assay is based on the selective inhibition of Amp-RT reactivity of Group M viruses by nevirapine, a non-nucleoside RT inhibitor. Group O viruses can be generically identified by the resistance of their Amp-RT activity to nevirapine. The assay can be used to screening of the blood supply and to rapidly differentiate group M from group O virus.

Potential Commercial Applications: Competitive Advantages:
  • Clinical monitoring of individual patient antiretroviral therapy
  • HIV/AIDS public health programs
  • Surveillance of retroviral drug resistance
  • Screening of blood donations
 
  • Rapid diagnostic which greatly reduces time and labor for improved clinical monitoring of HIV treatment
  • Ready for commercialization
  • Easily adapted to kit format
  • Assists continued usefulness of common antiretroviral therapeutics
  • Useful for high-throughput serum samples screening


Development Stage:
In vitro data available

Related Invention(s):
E-129-2013/0
E-129-2013/1


Inventors:

Walid Heneine (CDC)  ➽ more inventions...

Thomas Folks (CDC)  ➽ more inventions...

Shinji Yamamoto (CDC)  ➽ more inventions...

William Switzer (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 5,849,494 issued 1998-12-15
U.S. Pat: 6,136,534 issued 2000-10-24
US Application No. 09/123,012
US Application No. 08/379,851
Various international patents issued or pending

Publications:
Yamamoto S, et al. PMID 8882946
Heneine W, et al. PMID 7538549
Reisler RB, et al. PMID 11176273

Licensing Contact:
Karen Surabian, J.D., M.B.A.
Email: karen.surabian@nih.gov
Phone: 301-594-9719

OTT Reference No: E-232-1993/0
Updated: Jan 27, 2014